Catálogo de publicaciones - revistas

<jats:p>Analyses of DNA of Latinos in South Florida traced their African, European, and South American ancestries.</jats:p>

<jats:p>The National Science Foundation rebuffed a request from the chairman of the House of Representatives science committee for reviewer comments that helped the agency decide to fund five projects in the social sciences.</jats:p>

<jats:p>The most dramatic progress has been made on the twin prime conjecture and Goldbach's conjecture in more than a century and a half of trying.</jats:p>

<jats:p>The U.S. Department of Energy has funded a series of energy innovation hubs to tackle big energy challenges from start to finish. But their future is uncertain.</jats:p>

<jats:p>Wolves in an iconic predator-prey study are not producing pups, leaving scientists to confront a genetic rescue—or the project's demise.</jats:p>

<jats:p> The data reported in the Technical Comments by Fitz <jats:italic>et al</jats:italic> ., Price <jats:italic>et al</jats:italic> ., Tesseur <jats:italic>et al</jats:italic> ., and Veeraraghavalu <jats:italic>et al</jats:italic> . replicate and validate our central conclusion that bexarotene stimulates the clearance of soluble β-amyloid peptides and results in the reversal of behavioral deficits in mouse models of Alzheimer’s disease (AD). The basis of the inability to reproduce the drug-stimulated microglial-mediated reduction in plaque burden is unexplained. However, we concluded that plaque burden is functionally unrelated to improved cognition and memory elicited by bexarotene. </jats:p>

<jats:p> Cramer <jats:italic>et al</jats:italic> . (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrates short-term bexarotene treatment clearing preexisting β-amyloid deposits from the brains of APP/PS1ΔE9 mice with low amyloid burden, providing a rationale for repurposing this anticancer agent as an Alzheimer’s disease (AD) therapeutic. Using a nearly identical treatment regimen, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement. </jats:p>